ethylelediamine-folate | 197151-85-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethylelediamine-folate
• 英文别名: folate-(γ)-ethylenediamine；2-aminoethylfolic acid, γ-amide；(S)-2-(4-((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methylamino)benzamido)-5-(2-aminoethylamino)-5-oxopentanoic acid；N-(2-aminoethyl)folic acid；N²-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzoyl)-N⁵-(2-aminoethyl)-L-glutamine；folate-ϒ-ethylenediamine；ethylene diamine folate；folate-ethylenediamine；folate-EDA；folic acid γ-2-aminoethylamide；N2-(4-(((2-Amino-4-oxo-4,8-dihydropteridin-6-yl)methyl)amino)benzoyl)-N5-(2-aminoethyl)-L-glutamine；(2S)-5-(2-aminoethylamino)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-oxopentanoic acid
• CAS: 197151-85-2
• 化学式: C₂₁H₂₅N₉O₅
• 分子量: 483.487
• InChiKey: MUBZNOUNMFKTKG-AWEZNQCLSA-N

物化性质

• 密度：
  1.62±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.5
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  227
• 氢给体数：
  7
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  ethylelediamine-folate 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 2.33h， 生成 N2-(4-(((2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl)amino)benzoyl)-N5-(2-(((((5aS,6R,6aR)-1-benzyl-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl)methoxy)carbonyl)amino)ethyl)-L-glutamine
  参考文献：
  名称：

  “Click and go”: simple and fast folic acid conjugation

  摘要：

  提出了一种新颖的叶酸共轭方法，允许将叶酸与多种类型的分子（荧光探针）和材料（聚合物和硅胶）定量共轭，基于应变促进的炔-叠氮环加成，无需昂贵的色谱纯化。

  DOI：

  10.1039/c4ob00150h
• 作为产物：
  描述：

  L-谷氨酸-5-甲酯 以 二甲基亚砜 为溶剂， 反应 9.0h， 生成 ethylelediamine-folate
  参考文献：
  名称：

  Efficient Syntheses of Pyrofolic Acid and Pteroyl Azide, Reagents for the Production of Carboxyl-Differentiated Derivatives of Folic Acid

  摘要：

  Reaction of folic acid (1) with excess trifluoroacetic anhydride provides access to both the previously unknown N-10-(trifluoroacetyl)pyrofolic acid (8) and pyrofolic acid (9). Reaction of either of these materials with hydrazine selectively affords pteroyl hydrazide (13), which may be oxidized to pteroyl azide (27) on a large scale (62% overall from 1 without the need for chromatography). Treatment of 27 with differentially protected glutamates provides a convenient and high-yielding synthesis of differentially protected, optically pure folates.

  DOI：

  10.1021/ja971568j

文献信息

• [EN] CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS<br/>[FR] CELLULES T EXPRIMANT UN RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE ET PRODUITS THÉRAPEUTIQUES ANTICANCÉREUX
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2014100615A1

  公开（公告）日：2014-06-26

  Cytotoxic lymphocytes expressing chimeric antigen receptors (CAR) that target and bind small conjugate molecules (SCM) are disclosed, as well as methods of using the cells and the SCMs in the treatment of cancer.

  表达携带靶向和结合小共轭分子（SCM）的嵌合抗原受体（CAR）的细胞毒性淋巴细胞被揭示，以及在癌症治疗中使用这些细胞和SCM的方法。
• Light-controlled release of caged doxorubicin from folate receptor-targeting PAMAM dendrimer nanoconjugate
  作者：Seok Ki Choi、Thommey Thomas、Ming-Hsin Li、Alina Kotlyar、Ankur Desai、James R. Baker, Jr.

  DOI：10.1039/b927215c

  日期：——

  We report the synthesis and in vitro evaluation of folate receptor-targeted nanoconjugate that releases its therapeutic payload via a photochemical mechanism.

  我们报道了合成和体外评估靶向叶酸受体的纳米共轭物，该共轭物通过光化学机制释放其治疗负荷。
• Vitamin-Receptor Binding Drug Delivery Conjugates
  申请人：Endocyte, Inc.

  公开号：US20160220694A1

  公开（公告）日：2016-08-04

  The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

  该发明描述了一种维生素受体结合药物传递共轭物及其制备方法。药物传递共轭物由维生素受体结合基团、双价连接剂（L）和药物组成。维生素受体结合基团包括维生素、维生素受体结合类似物及其衍生物，药物包括类似物及其衍生物。维生素受体结合基团与双价连接剂共价连接，药物或其类似物或衍生物与双价连接剂共价连接，其中双价连接剂（L）包括间隔连接剂、可释放连接剂和杂原子连接剂以及其组合。还描述了利用该药物传递共轭物消除病原细胞群的方法和药物组合物。
• Towards potent but less toxic nanopharmaceuticals – lipoic acid bioconjugates of ultrasmall gold nanoparticles with an anticancer drug and addressing unit
  作者：Maciej Dzwonek、Dominika Załubiniak、Piotr Piątek、Grzegorz Cichowicz、Sylwia Męczynska-Wielgosz、Tomasz Stępkowski、Marcin Kruszewski、Agnieszka Więckowska、Renata Bilewicz

  DOI：10.1039/c8ra01107a

  日期：——

  Modification of ultrasmall gold nanoparticles (AuNPs) with the lipoic acid derivative of folic acid was found to enhance their accumulation in the cancer cell, as compared to AuNPs without addressing units.

  将超小金纳米颗粒（AuNPs）修饰为叶酸的硫辛酸衍生物被发现可以增强它们在癌细胞中的积聚，相较于未处理单元的AuNPs。
• [EN] COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY<br/>[FR] COMPOSITIONS ET MÉTHODES DE THÉRAPIE PAR LYMPHOCYTES T CAR
  申请人：ENDOCYTE INC

  公开号：WO2018160622A1

  公开（公告）日：2018-09-07

  The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

  本公开涉及通过向患有癌症的患者输入含有CAR T细胞和通过连接物与靶向基团相连接的小分子的组合物来治疗患者的方法。该公开还涉及用于此类方法的组合物。